Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Topotecan as a Continuous Infusion Over 14 Days in Recurrent Ovarian Cancer Patients

D. DENSCHLAG, D. WATERMANN, K. HÖRIG, C. KISSEL, C. TEMPFER and G. GITSCH
Anticancer Research March 2004, 24 (2C) 1267-1270;
D. DENSCHLAG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. WATERMANN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. HÖRIG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. KISSEL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. TEMPFER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. GITSCH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 24 no. 2C 1267-1270
PMID 
15154658

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received November 10, 2003
  • Accepted February 3, 2004
  • Published online March 1, 2004.

Copyright & Usage 
Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. D. DENSCHLAG,
  2. D. WATERMANN,
  3. K. HÖRIG,
  4. C. KISSEL,
  5. C. TEMPFER and
  6. G. GITSCH
  1. Department of Gynecology and Obstetrics, University of Freiburg School of Medicine, Freiburg, Germany
  1. Correspondence to: Dominik Denschlag, MD, Dept. of Obstetrics and Gynecology, University of Freiburg Medical School, Hugstetter Strasse 55, D-79106 Freiburg, Germany. Tel: +49-761-2703002, Fax: +49-761-2703037, e-mail: ddenschl{at}frk.ukl.uni-freiburg.de

Statistics from Altmetric.com

Cited By...

  • 4 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 24, Issue 2C
March-April 2004
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Topotecan as a Continuous Infusion Over 14 Days in Recurrent Ovarian Cancer Patients
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Topotecan as a Continuous Infusion Over 14 Days in Recurrent Ovarian Cancer Patients
D. DENSCHLAG, D. WATERMANN, K. HÖRIG, C. KISSEL, C. TEMPFER, G. GITSCH
Anticancer Research Mar 2004, 24 (2C) 1267-1270;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Topotecan as a Continuous Infusion Over 14 Days in Recurrent Ovarian Cancer Patients
D. DENSCHLAG, D. WATERMANN, K. HÖRIG, C. KISSEL, C. TEMPFER, G. GITSCH
Anticancer Research Mar 2004, 24 (2C) 1267-1270;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Real-world Comparative Study of Androgen Receptor Signaling Inhibitors in Japanese Patients With Non-metastatic Castration-resistant Prostate Cancer
  • Adverse Events and Safety Outcomes Associated With Chemotherapy for Inflammatory Bowel Disease–associated Gastrointestinal Cancers
  • Prognostic Impact of Early GNRI Sustainability in Metastatic Urothelial Carcinoma Receiving Pembrolizumab
Show more Clinical Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire